Literature DB >> 27386773

Functional Status, Pulmonary Artery Pressure, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction.

Daniel Dalos1, Julia Mascherbauer1, Caroline Zotter-Tufaro1, Franz Duca1, Andreas A Kammerlander1, Stefan Aschauer1, Diana Bonderman2.   

Abstract

BACKGROUND: Patients with heart failure with preserved ejection fraction have functional impairment resulting in reduced quality of life. Specific pathological mechanisms underlying symptoms have not yet been defined.
OBJECTIVES: The aim of this study was to identify hemodynamic and other patient-related variables that are associated with New York Heart Association (NYHA) functional class and to analyze functional class in perspective with other clinical, laboratory, imaging, and hemodynamic parameters with respect to its influence on outcomes.
METHODS: Between January 2011 and February 2015, 193 patients with confirmed heart failure with preserved ejection fraction were enrolled.
RESULTS: Those in more advanced NYHA functional classes (III and IV; n = 136) were older (p = 0.008), had higher body mass indexes (p = 0.004), and had higher levels of N-terminal pro-brain natriuretic peptide (p = 0.001) compared with less symptomatic patients (NYHA class II; n = 57). Furthermore, parameters reflecting left ventricular diastolic dysfunction were more pronounced in advanced NYHA classes (early mitral inflow velocity/early diastolic mitral annular velocity; p = 0.023) as well as parameters reflecting right ventricular afterload (diastolic pulmonary artery pressure; p < 0.001). By multivariate regression analysis, age (p = 0.007), body mass index (p = 0.002), N-terminal pro-brain natriuretic peptide (p < 0.001), early mitral inflow velocity/mitral peak velocity of late filling (p = 0.031), and diastolic pulmonary artery pressure (p < 0.001) were independently associated with advanced NYHA class. After 21.9 months of follow-up, 64 patients (33.2%) reached the combined endpoint, defined as hospitalization for heart failure and/or cardiac death. By multivariate Cox analysis, NYHA functional class was independently associated with outcome (hazard ratio: 2.133; p = 0.040), as well as N-terminal pro-brain natriuretic peptide (hazard ratio: 1.655; p < 0.001) and impaired right ventricular function (hazard ratio: 2.360; p = 0.001).
CONCLUSIONS: Symptoms of breathlessness in patients with heart failure with preserved ejection fraction are multifactorial and largely related to body mass index, left ventricular diastolic function, and the pulmonary vasculature. Clinically meaningful therapeutic interventions should target body weight, left ventricular stiffness, and concomitant pulmonary vascular disease.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  functional capacity; heart failure; outcome

Mesh:

Year:  2016        PMID: 27386773     DOI: 10.1016/j.jacc.2016.04.052

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  30 in total

1.  Coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction.

Authors:  Kathryn Dryer; Mark Gajjar; Nikhil Narang; Margaret Lee; Jonathan Paul; Atman P Shah; Sandeep Nathan; Javed Butler; Charles J Davidson; William F Fearon; Sanjiv J Shah; John E A Blair
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-02-09       Impact factor: 4.733

Review 2.  Pulmonary Hypertension in Heart Failure Patients: Pathophysiology and Prognostic Implications.

Authors:  Marco Guazzi; Valentina Labate
Journal:  Curr Heart Fail Rep       Date:  2016-12

3.  Performance status and in-hospital mortality of elderly patients with community acquired pneumonia.

Authors:  Filippo Pieralli; Vieri Vannucchi; Giulia De Marzi; Antonio Mancini; Francesca Bacci; Ombretta Para; Carlo Nozzoli; Marco Falcone
Journal:  Intern Emerg Med       Date:  2018-03-09       Impact factor: 3.397

4.  The MAGGIC risk score predicts mortality in patients undergoing transcatheter aortic valve replacement: sub-analysis of the OCEAN-TAVI registry.

Authors:  Hirofumi Hioki; Yusuke Watanabe; Ken Kozuma; Hideyuki Kawashima; Fukuko Nagura; Makoto Nakashima; Akihisa Kataoka; Masanori Yamamoto; Toru Naganuma; Motoharu Araki; Norio Tada; Shinichi Shirai; Futoshi Yamanaka; Akihiro Higashimori; Kazuki Mizutani; Minoru Tabata; Kensuke Takagi; Hiroshi Ueno; Kentaro Hayashida
Journal:  Heart Vessels       Date:  2019-05-29       Impact factor: 2.037

Review 5.  Insights into the pulmonary vascular complications of heart failure with preserved ejection fraction.

Authors:  Yen-Chun Lai; Longfei Wang; Mark T Gladwin
Journal:  J Physiol       Date:  2018-12-30       Impact factor: 5.182

Review 6.  Heart Failure with Preserved Ejection Fraction in Older Adults.

Authors:  Bharathi Upadhya; Dalane W Kitzman
Journal:  Heart Fail Clin       Date:  2017-05-06       Impact factor: 3.179

7.  Hemodynamic Effects of Weight Loss in Obesity: A Systematic Review and Meta-Analysis.

Authors:  Yogesh N V Reddy; Mahesh Anantha-Narayanan; Masaru Obokata; Katlyn E Koepp; Patricia Erwin; Rickey E Carter; Barry A Borlaug
Journal:  JACC Heart Fail       Date:  2019-07-10       Impact factor: 12.035

8.  Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction.

Authors:  Masaru Obokata; Yogesh N V Reddy; Sorin V Pislaru; Vojtech Melenovsky; Barry A Borlaug
Journal:  Circulation       Date:  2017-04-05       Impact factor: 29.690

Review 9.  Imaging and Management of Heart Failure and Preserved Ejection Fraction.

Authors:  Fernando Telles; Thomas H Marwick
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-09-27

10.  Association of Obesity With Adverse Long-term Outcomes in Hypertrophic Cardiomyopathy.

Authors:  Carlo Fumagalli; Niccolò Maurizi; Sharlene M Day; Euan A Ashley; Michelle Michels; Steven D Colan; Daniel Jacoby; Niccolò Marchionni; Justin Vincent-Tompkins; Carolyn Y Ho; Iacopo Olivotto
Journal:  JAMA Cardiol       Date:  2020-01-01       Impact factor: 14.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.